Table 1. Baseline characteristics of non-HIV PCP patients with respiratory failure.
| Variable | n = 81 |
|---|---|
| Median age, years (IQR) | 60.9 (50.0–71.5) |
| Male sex, n (%) | 51 (63.0%) |
| Ever smoking, n (%) | 36 (44.4%) |
| APACHE II score, median (IQR) | 21.1 (16.0–25.0) |
| Comorbidity, n (%) | |
| Hypertension | 46 (56.8%) |
| Diabetes mellitus | 23 (28.4%) |
| Congestive heart failure | 6 (7.4%) |
| Cerebrovascular disease | 4 (4.9%) |
| Chronic renal failure | 25 (30.9%) |
| Chronic liver disease | 8 (9.9%) |
| Chronic obstructive lung disease | 4 (4.9%) |
| Underlying disease, n (%) | |
| Solid malignancy | 29 (35.8%) |
| Hematologic malignancy | 14 (17.3%) |
| Solid organ transplantation | 16 (19.8%) |
| Rheumatologic disease | 7 (8.6%) |
| Others† | 15 (18.5%) |
| Previous treatment, n (%) | |
| Chemotherapy or Radiotherapy | 43 (53.1%) |
| Corticosteroid use >3 months | 27 (33.3%) |
| Cyclosporine, mycophenolate, tacrolimus, sirolimus, or methotrexate | 20 (24.7%) |
| CMV quantitative real-time PCR positive in blood sample, n (%) | 43 (53.1%) |
| Second-line treatment, n (%)‡ | 19 (23.5%) |
| Respiratory samples, n (%) | |
| BAL fluids | 5 (6.2%) |
| Endotracheal aspiration | 51 (63.0%) |
| Induced sputum | 6 (7.4%) |
| BAL fluids and either endotracheal aspiration or induced sputum | 19 (23.5%) |
IQR, interquartile range; CMV; cytomegalovirus
†Others: Interstitial lung disease on steroid use, membranous glomerulonephritis, focal segmental glomerulosclerosis
‡ Second-line treatment: primaquine and clindamycin in 18 patients and pentamidine in 1 patient